<DOC>
	<DOCNO>NCT02233244</DOCNO>
	<brief_summary>This drug-drug interaction study assess potential CTX-4430 induce CYP3A activity healthy subject . The study hypothesis midazolam ( sensitive , widely use CYP3A4 substrate ) blood level change treatment CTX-4430 .</brief_summary>
	<brief_title>Drug-Drug Interaction Study Evaluate Pharmacokinetics Safety CTX 4430 Midazolam</brief_title>
	<detailed_description />
	<mesh_term>Midazolam</mesh_term>
	<criteria>Healthy adult male female , 1855 year age , inclusive screen Continuous nonsmoker use nicotinecontaining product least 3 month prior first dose Body Mass Index ( BMI ) ≥ 18.5 ≤ 32.0 kg/m2 screen Medically healthy clinically significant medical history , physical examination , laboratory profile , vital sign ECGs , deem PI For female childbearing potential : either sexually inactive ( true abstinence line prefer usual lifestyle subject ) 14 day prior first dose throughout study use one follow acceptable birth control method : 1. nonhormone release intrauterine device place least 3 month prior first dose physical ( e.g . condom diaphragm ) chemical barrier ( e.g . spermicide ) time screen 14 day follow last dose 2. double physical barrier ( e.g . condom diaphragm ) chemical barrier ( e.g . spermicide ) time screen 14 day follow last dose 3. surgical sterilization partner ( vasectomy 180 day minimum ) physical ( e.g . condom diaphragm ) chemical barrier ( e.g . spermicide ) time screen 14 day follow last dose . 4. exclusive nonheterosexual lifestyle In addition , female subject childbearing potential advise remain sexually inactive keep birth control method least 14 day follow last dose Female non childbearing potential : must undergo one follow sterilization procedure least 6 month prior first dose : 1. hysteroscopy sterilization ( copy confirmation test ) use physical ( e.g . condom diaphragm ) chemical barrier ( e.g . spermicide ) barrier method ( e.g. , condom diaphragm ) spermicide throughout study 2. bilateral tubal ligation bilateral salpingectomy use physical ( e.g . condom diaphragm ) chemical barrier ( e.g . spermicide ) barrier method ( e.g. , condom diaphragm ) spermicide throughout study 3. hysterectomy 4. bilateral oophorectomy postmenopausal amenorrhea least 1 year prior first dose FSH serum level consistent postmenopausal status A non vasectomize , male subject must agree use condom spermicide abstain sexual intercourse study 90 day beyond last dose study drug . ( No restriction require vasectomized male provide vasectomy perform 4 month prior study start . A male vasectomized less 4 month prior study start must follow restriction non vasectomized male ) If male , must agree donate sperm first dose 90 day dose A subject claim sexually inactive need remain inactive whole study duration Understands study procedure inform consent form ( ICF ) , willing able comply protocol Subject mentally legally incapacitated significant emotional problem time screen visit expect conduct study History presence clinically significant medical psychiatric condition disease opinion PI History illness , opinion PI , might confound result study pose additional risk subject participation study History presence chronic alcohol drug abuse past 2 year prior screen History presence hypersensitivity idiosyncratic reaction study drug ( ) relate compound ( e.g. , benzodiazepine midazolam since cross sensitivity benzodiazepine possible ) component midazolam solution formulation Subject currently take history pronounce sedation upon take benzodiazepine sedative/soporific drug Female subject pregnant lactate Positive urine drug result screen checkin positive alcohol result check Drink alcohol excess 21 glasses/units per week male 14 glasses/units per week female , one unit = 150 mL wine 360 mL beer 45 mL 45 % alcohol Positive urine cotinine screen Positive result screen HIV , HBsAg HCV Seated blood pressure le 90/40 mmHg great 140/90 mmHg screening Seated heart rate lower 40 bpm high 99 bpm screen QTcF interval &gt; 430 msec ( male ) &gt; 450 msec ( female ) deem clinically abnormal PI Unable refrain anticipates use : Any drug , include prescription non prescription medication , herbal remedy , vitamin supplement begin 14 day prior first dose study drug throughout study . Hormonal contraceptives hormone replacement therapy allow . Paracetamol ( 2 g per 24 hour period ) may permit study . Any drug , food , herbal preparation know significant inducer CYP enzymes and/or Pgp , include St. John 's Wort , 28 day prior first dose study drug throughout study . Appropriate source consult PI designee confirm lack PK/PD interaction study drug . Have diet incompatible study diet , opinion PI , within 28 day prior first dose study drug ( ) , throughout study Donation blood plasma within 90 day prior first dose study drug Donation bone marrow within last 6 month prior first dose study drug Participation another clinical trial within 90 day prior first dose study drug . The 90 day window derive date last study schedule blood collection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>Drug Interaction</keyword>
</DOC>